Synopsys (SNPS) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

A Dual Eligible Special Needs plan provides special coverage for people who are eligible for both Medicare and Medicaid. The plan is one of several Special Needs plans (SNPs), a type of Medicare ...

With the new availability of Medicare enrollment data for 2025, we examine ongoing enrollment growth of chronic condition ...

Synopsys (SNPS), a software company, is set to release its Q4 2024 results on December 4. Wall Street analysts expect the company to report earnings of $3.30 per share for Q3, up 4% year-over-year.

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...

Medicare offers Special Needs Plans (SNPs) to people with certain conditions or medical needs. Chronic Condition Special Needs Plans (C-SNPs) are plans for individuals with specific chronic conditions ...

This is the latest in the Health Affairs Forefront featured topic, Medicare and Medicaid Integration. The featured topic includes analysis, proposals, and commentary that will inform policies on the ...

C-SNPs are Medicare Advantage (Part C) plans designed for people with chronic conditions. To be eligible, you must qualify for Medicare. Benefits vary by plan, but plans always include prescription ...

Synopsys (SNPS) closed at $492.89 in the latest trading session, marking a -1.81% move from the prior day. The stock's change was less than the S&P 500's daily loss of 1.54%. Elsewhere, the Dow lost 1 ...

D-SNPs are for individuals who qualify for both Medicare and Medicaid, regardless of their overall health status. (Judita Mikalkevičė, Judita Mikalkevičė via Pexels.) The advertiser paid a fee to ...

Synopsys (SNPS) stock is down 35.8% in a day. The sell-off comes as the semiconductor design software vendor posted quarterly results that missed analysts’ expectations, while also lowering its ...